HPV vaccination and risk of chronic fatigue syndrome/myalgic encephalomyelitis: A nationwide register-based study from Norway

“…It is equally tempting to implicate HPV vaccine materials as being capable of causing CFS/ME, FM, POTS, CRPS, SFN and AD. Recent publications, however, from Canada, Norway and France, done with proper methodology, have negated most if not all of these associations despite the demonstration of low titer autoantibodies in subsets of symptomatic patients following HPV vaccination [8][9][10]. Does that make short shrift of proponents' claims of HPV vaccine-induced illness?…”

Section: Discussionmentioning

confidence: 99%

Hidden Toxicity of Human Papillomavirus Vaccine Ingredients

E¹

2019

J Rheum Dis Treat

View full text Add to dashboard Cite

show abstract

“…A Cochrane review from 2018 [3] and most large epidemiological studies [16][17][18][19][20] did not find serious or general harms associated with the HPV vaccines. The Cochrane review was mainly based on journal publications that often are influenced by reporting bias [21][22][23][24], and epidemiological studies are influenced by confounding [25].…”

Section: Uncertainties Of the Harms Of The Hpv Vaccinesmentioning

confidence: 96%

Benefits and harms of the human papillomavirus (HPV) vaccines: systematic review with meta-analyses of trial data from clinical study reports

2020

View full text Add to dashboard Cite

Objective: To assess the benefits and harms of the human papillomavirus (HPV) vaccines. Data sources: Clinical study reports obtained from the European Medicines Agency and GlaxoSmithKline from 2014 to 2017. Eligibility criteria: Randomised trials that compared an HPV vaccine with a placebo or active comparator in healthy participants of all ages. Appraisal and synthesis: Two researchers extracted data and judged risk of bias with the Cochrane tool (version 2011). Risk ratio (RR) estimates were pooled using random-effects meta-analysis. Outcomes: Clinically relevant outcomes in intention to treat populations-including HPV-related cancer precursors irrespective of involved HPV types, treatment procedures and serious and general harms. Results: Twenty-four of 50 eligible clinical study reports were obtained with 58,412 pages of 22 trials and 2 followup studies including 95,670 participants: 79,102 females and 16,568 males age 8-72; 393,194 person-years; and 49 months mean weighted follow-up. We judged all 24 studies to be at high risk of bias. Serious harms were incompletely reported for 72% of participants (68,610/95,670). Nearly all control participants received active comparators (48,289/48,595, 99%). No clinical study report included complete case report forms. At 4 years followup, the HPV vaccines reduced HPV-related carcinoma in situ (367 in the HPV vaccine group vs. 490 in the comparator group, RR 0.73 [95% confidence interval, CI, 0.53 to 1.00], number needed to vaccinate [NNV] 387, P = 0.05, I 2 = 67%) and HPV-related treatment procedures (1018 vs. 1416, RR 0.71 [95% CI 0.63 to 0.80], NNV 75, P < 0.00001, I 2 = 45%). The HPV vaccines increased serious nervous system disorders (exploratory analysis: 72 vs. 46, RR 1.49 [1.02 to 2.16], number needed to harm [NNH] 1325, P = 0.040, I 2 = 0%) and general harms (13,248 vs. 12,394, RR 1.07 [95% CI 1.03 to 1.11], NNH 51, P = 0.0002, I 2 = 77%) but did not significantly increase fatal harms (45 vs. 38, RR 1.19 [95% CI 0.65 to 2.19], P = 0.58, I 2 = 30%) or serious harms (1404 vs. 1357, RR 1.01 [95% CI 0.94 to 1.08], P = 0.79, I 2 = 0%).

show abstract

HPV vaccination and risk of chronic fatigue syndrome/myalgic encephalomyelitis: A nationwide register-based study from Norway

Abstract: No indication of increased risk of CFS/ME following HPV vaccination was observed among girls in the first 6 birth cohorts offered HPV vaccine through the national immunisation programme in Norway.

Cited by 52 publications

References 51 publications

Challenges of independent assessment of potential harms of HPV vaccines

Challenges of independent assessment of potential harms of HPV vaccines

Hidden Toxicity of Human Papillomavirus Vaccine Ingredients

Benefits and harms of the human papillomavirus (HPV) vaccines: systematic review with meta-analyses of trial data from clinical study reports

Contact Info

Product

Resources

About